Last $27.92 USD
Change Today +0.70 / 2.57%
Volume 1.0M
WMGI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
NASDAQ GM
As of 8:10 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

wright medical group inc (WMGI) Snapshot

Open
$27.21
Previous Close
$27.22
Day High
$27.95
Day Low
$27.02
52 Week High
02/24/14 - $33.80
52 Week Low
04/30/14 - $26.76
Market Cap
1.4B
Average Volume 10 Days
782.0K
EPS TTM
$-3.90
Shares Outstanding
51.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WRIGHT MEDICAL GROUP INC (WMGI)

wright medical group inc (WMGI) Related Bloomberg News

View More Bloomberg News

wright medical group inc (WMGI) Related Businessweek News

No Related Businessweek News Found

wright medical group inc (WMGI) Details

Wright Medical Group, Inc., a specialty orthopaedic company, provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company offers products that are used primarily in foot and ankle repair, upper extremity products, and biologics products. Its extremity hardware products comprise implants and other devices to replace or reconstruct injured or diseased joints and bones of the foot, ankle, hand, wrist, fingers, toes, elbow, and shoulder. The company also provides biologic products, which are used to replace damaged or disease bone, stimulate bone growth, and provide other biological solutions for surgeons and their patients, as well as offers a bone graft product incorporating antibiotic delivery. Its biological products focus on supporting biological musculoskeletal repair by utilizing synthetic and human tissue-based materials. The company sells its products through a network of employee sales representatives, independent sales representatives, and stocking distributors in approximately 60 countries primarily in the United States, Europe, Asia, Canada, Australia, and Latin America. The company was founded in 1950 and is headquartered in Memphis, Tennessee.

898 Employees
Last Reported Date: 02/27/14
Founded in 1950

wright medical group inc (WMGI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $750.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $340.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $500.0K
President of International
Total Annual Compensation: $564.0K
Senior Vice President and General Manager of ...
Total Annual Compensation: $318.3K
Compensation as of Fiscal Year 2013.

wright medical group inc (WMGI) Key Developments

Wright Medical Group Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Wright Medical Group Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

Wright Medical Group Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM

Wright Medical Group Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Robert J. Palmisano, Chief Executive Officer, President and Director.

Wright Medical Group Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014; Provides Production Guidance for the Year 2014

Wright Medical Group Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $71,307,000 compared to $57,641,000 a year ago. Operating loss was $20,649,000 compared to $232,559,000 a year ago. Loss from continuing operations before income taxes was $46,644,000 compared to $172,584,000 a year ago. Net loss from continuing operations was $49,647,000 or $0.99 per diluted share compared to $124,500,000 or $2.68 per diluted share a year ago. Net loss was $61,807,000 or $1.24 per diluted share compared to $130,020,000 or $2.80 per diluted share a year ago. Operating loss, as adjusted was $15,026,000 compared to $11,473,000 a year ago. Adjusted LBITDA was $5,869,000 compared to $4,769,000 a year ago. Loss before taxes, as adjusted was $17,439,000 compared to $13,458,000 a year ago. Net loss, as adjusted was $17,666,000 compared to $8,208,000 a year ago. Net loss from continuing operations, as adjusted, per diluted share was $0.35 compared to $0.18 a year ago. Net cash used in operating activities was $34,562,000 compared to $34,000 a year ago. Capital expenditures were $11,422,000 compared to $12,777,000 a year ago. For the nine months, the company reported net sales of $214,733,000 compared to $174,506,000 a year ago. Operating loss was $72,866,000 compared to $258,966,000 a year ago. Loss from continuing operations before income taxes was $140,725,000 compared to $205,654,000 a year ago. Net loss from continuing operations was $133,528,000 or $2.70 per diluted share compared to $144,957,000 or $3.24 per diluted share a year ago. Net loss was $148,453,000 or $3.00 per diluted share compared to $138,916,000 or $3.11 per diluted share a year ago. Operating loss, as adjusted was $51,514,000 compared to $23,774,000 a year ago. Adjusted LBITDA was $23,620,000 compared to $2,779,000 a year ago. Loss before taxes, as adjusted was $57,444,000 compared to $29,111,000 a year ago. Net loss, as adjusted was $58,187,000 compared to $17,341,000 a year ago. Net loss from continuing operations, as adjusted, per diluted share was $1.18 compared to $0.39 a year ago. Net cash used in operating activities was $86,152,000 compared to $5,721,000 a year ago. Capital expenditures were $35,706,000 compared to $22,512,000 a year ago. The company anticipates net sales from continuing operations, or Extremity and Biologics revenue, for 2014 of approximately $298 million to $302 million, representing growth of 23% to 25% from 2013, compared to previous guidance of $308 million to $312 million. The company anticipates 2014 adjusted EBITDA from continuing operations, of negative $23.0 million to negative $26.0 million. The company anticipates adjusted loss earnings per share from continuing operations, including stock-based compensation, for full-year 2014 of $1.40 to $1.46 per diluted share. The company will not has a tax benefit in 2014, and still expect full year tax rate to be roughly 0. The company expects to achieve productivity goal in of $1 million per rep rate, exiting 2014, assuming revised guidance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WMGI:US $27.92 USD +0.70

WMGI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $55.09 USD +0.83
Exactech Inc $22.69 USD +0.69
ICU Medical Inc $83.08 USD +2.68
Thoratec Corp $31.55 USD +0.99
Tornier NV $26.51 USD +0.57
View Industry Companies
 

Industry Analysis

WMGI

Industry Average

Valuation WMGI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WRIGHT MEDICAL GROUP INC, please visit www.wmt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.